(Q37640907)

21 August 2017

1 reference

title

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management (English)

1 reference

Duchenne muscular dystrophy

21 August 2017

0 references

1 reference

1 reference

Laura E Case

4

0 references

David J Birnkrant

object named as

David J Birnkrant

3

0 references

Craig M. McDonald

object named as

Craig McDonald

9

0 references

author name string

Katharine Bushby

1

1 reference

21 August 2017

Richard Finkel

2

1 reference

21 August 2017

Paula R Clemens

5

1 reference

21 August 2017

Linda Cripe

6

1 reference

21 August 2017

Ajay Kaul

7

1 reference

21 August 2017

Kathi Kinnett

8

1 reference

21 August 2017

Shree Pandya

10

1 reference

21 August 2017

James Poysky

11

1 reference

21 August 2017

Frederic Shapiro

12

1 reference

21 August 2017

Jean Tomezsko

13

1 reference

21 August 2017

Carolyn Constantin

14

1 reference

21 August 2017

DMD Care Considerations Working Group

15

1 reference

21 August 2017

publication date

27 November 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

77-93

1 reference

Neonatal screening for Duchenne muscular dystrophy: a novel semiquantitative application of the bioluminescence test for creatine kinase in a pilot national program in Cyprus

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Population frequencies of inherited neuromuscular diseases—A world survey

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Failure of early diagnosis in symptomatic Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Behavior patterns in Duchenne muscular dystrophy: report on the Parent Project Muscular Dystrophy behavior workshop 8-9 of December 2006, Philadelphia, USA.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Dystrophin: the protein product of the Duchenne muscular dystrophy locus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 1. Trends across the clinical groups

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

The role of cytoskeletal proteins in cardiomyopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Molecular genetics of left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Dystrophin and mutations: one gene, several proteins, multiple phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Variability in clinical, genetic and protein abnormalities in manifesting carriers of Duchenne and Becker muscular dystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Dystrophinopathy in isolated cases of myopathy in females

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Molecular studies of progressive muscular dystrophy (Duchenne)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Genetic treatments in muscular dystrophies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Glucocorticoid corticosteroids for Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

The Duchenne muscular dystrophy population in Denmark, 1977-2001: prevalence, incidence and survival in relation to the introduction of ventilator use.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

A new lease on life for patients with Duchenne muscular dystrophy in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Managing Duchenne muscular dystrophy--the additive effect of spinal surgery and home nocturnal ventilation in improving survival

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Report on the muscular dystrophy campaign workshop: exercise in neuromuscular diseases Newcastle, January 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Evaluation of a program for long-term treatment of Duchenne muscular dystrophy. Experience at the University Hospitals of Cleveland

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Adult life with Duchenne muscular dystrophy: observations among an emerging and unforeseen patient population.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Developmental progress in Duchenne muscular dystrophy: lessons for earlier detection.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Experience and strategy for the molecular testing of Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Deletion and duplication screening in the DMD gene using MLPA.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Rapid direct sequence analysis of the dystrophin gene

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Technology insight: therapy for Duchenne muscular dystrophy-an opportunity for personalized medicine?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Local dystrophin restoration with antisense oligonucleotide PRO051

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Is a muscle biopsy in Duchenne dystrophy really necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

The use of percutaneous needle muscle biopsy in the diagnosis of myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

The utility of muscle biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Clinical trials in Duchenne dystrophy. Standardization and reliability of evaluation procedures

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Reliability of goniometric measurements in patients with Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Clinical trial in Duchenne dystrophy. I. The design of the protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

The role of the dystrophin-glycoprotein complex in the molecular pathogenesis of muscular dystrophies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

The pathomechanics of gait in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

The role of corticosteroids in muscular dystrophy: a critical appraisal

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Steroids in duchenne muscular dystrophy — Deflazacort trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Long-term benefit from prednisone therapy in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Relationship between systemic corticosteroid exposure and growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Interactions between growth and body composition in children treated with high-dose chronic glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Adverse psychological effects of corticosteroids in children and adolescents.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Neuropsychological and behavioral changes in asthmatic children treated with beclomethasone dipropionate versus theophylline.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Proposals for prevention and management of steroid-induced osteoporosis in children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Myoglobinuria in boys with Duchenne muscular dystrophy on corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Clinical investigation in duchenne dystrophy: 2. Determination of the ?power? of therapeutic trials based on the natural history

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

145th ENMC International Workshop: planning for an International Trial of Steroid Dosage Regimes in DMD (FOR DMD), 22-24th October 2006, Naarden, The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Deflazacort treatment of Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Cognitive and adaptive deficits in young children with Duchenne muscular dystrophy (DMD).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Diagnosis of Duchenne muscular dystrophy: parents' experiences and satisfaction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Parental stress in mothers of boys with duchenne muscular dystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Brain function in Duchenne muscular dystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Psychosocial adjustment in males with Duchenne muscular dystrophy: psychometric properties and clinical utility of a parent-report questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Selective deficits in verbal working memory associated with a known genetic etiology: the neuropsychological profile of duchenne muscular dystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Delayed developmental language milestones in children with Duchenne's muscular dystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Association between intellectual functioning and age in children and young adults with Duchenne muscular dystrophy: further results from a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Are males with Duchenne muscular dystrophy at risk for reading disabilities?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Neuropsychiatric disorders in males with duchenne muscular dystrophy: frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive--compulsive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

Depression in parents of children with Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2809%2970271-6

7 January 2021

10.1016/S1474-4422(09)70271-6

Identifiers

DOI

1 reference

21 August 2017

1 reference